Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Pioneer HoldingHKSE:01345 -1.75%73 EBITDA Margin % is 13.50% as of Dec. 2025, which is 8% below its 10-year median of 14.60. GuruFocus rates HKSE:01345 with a GF Score™ of 73/100 and a GF Value™ of HK$1.80 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 663 Healthcare Providers & Services companies, Shanghai Pioneer Holding ranks better than 54.9% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Shanghai Pioneer Holding EBITDA Margin % Related Terms
Shanghai Pioneer Holding EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Shanghai Pioneer Holding's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Pioneer Holding EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Shanghai Pioneer Holding's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Shanghai Pioneer Holding's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Pioneer Holding (HKSE:01345) has a EBITDA Margin % of 13.50% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shanghai Pioneer Holding and its competitors. This is near median its historical median of 14.60. Over the past decade, Shanghai Pioneer Holding's EBITDA Margin % has ranged from 7.18 to 19.91. According to the industry distribution chart, Shanghai Pioneer Holding ranks #299 out of 663 companies in the Healthcare Providers & Services industry, placing it in the top 45.1%.
Is Shanghai Pioneer Holding's EBITDA Margin % too high?
Shanghai Pioneer Holding's current EBITDA Margin % of 13.50% is near median its 10-year median of 14.60. Over the past 10 years, this metric has ranged from a low of 7.18 to a high of 19.91. The Healthcare Providers & Services industry median EBITDA Margin % is 10.23. Shanghai Pioneer Holding's value of 13.50% is 32% above this industry median. Based on the distribution chart, Shanghai Pioneer Holding ranks #299 out of 663 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Shanghai Pioneer Holding has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Pioneer Holding's EBITDA Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Shanghai Pioneer Holding ranks #299 out of 663 companies for EBITDA Margin %. This puts Shanghai Pioneer Holding in the upper half of its industry. The industry median EBITDA Margin % is 10.23. Shanghai Pioneer Holding's value of 13.50% is 32% above this benchmark. Historically, Shanghai Pioneer Holding's own EBITDA Margin % has ranged from 7.18 to 19.91 over the past decade. While the company's 10-year median is 14.60 vs. the industry median of 10.23, Shanghai Pioneer Holding has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.23, based on 663 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Pioneer Holding's current EBITDA Margin % of 13.50% is 32% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shanghai Pioneer Holding and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Pioneer Holding's current EBITDA Margin % is 13.50%, which is near median its own 10-year median of 14.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Pioneer Holding stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Pioneer Holding (HKSE:01345) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$1.80, compared to a current price of HK$2.25 — trading 25% above its estimated fair value. The current EBITDA Margin % is 13.50%, which is near median its 10-year median of 14.60 and 32% above the Healthcare Providers & Services industry median of 10.23. Shanghai Pioneer Holding's overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Shanghai Pioneer Holding (HKSE:01345), the current EBITDA Margin % is 13.50% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Pioneer Holding (HKSE:01345) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Pioneer Holding stock appears to be overvalued.
The current stock price of HK$2.25 is trading 25% above its estimated GF Value™ of HK$1.80.
GuruFocus considers Shanghai Pioneer Holding to be Modestly Overvalued.
Key valuation signals for HKSE:01345:
EBITDA Margin %: 13.50% (near median its 10-year median of 14.60)
GF Value™: HK$1.80 vs. price of HK$2.25 (25% above fair value)
Industry Position: 32% above the Healthcare Providers & Services median (#299 of 663)
No single metric tells the full story. See the HKSE:01345 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Pioneer Holding Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the marketing, promotion, sales, and channel management service for imported pharmaceutical products and medical devices in China. The company has a portfolio of pharmaceutical products, covering ophthalmology, pain management, cardiovascular, gastroenterology, immunology, gynecology, and other therapeutic areas, and medical devices covering several medical specialties, including ophthalmology, odontology, cardiology and wound care products. The majority of its revenue derives from the Sales of medical equipment and supplies. The group operates mainly in the People's Republic of China.
73GF Score
Get the complete analysis for HKSE:01345
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01345 has been successfully added to your 
